OK-432 therapy for lymphangioma in children: Why and how does it work?

Journal of Pediatric Surgery

Volumn 31, Issue 4, 1996, Pages 477-480

  Ogita, Shuhei ^a   Tsuto, Toshiaki ^a   Nakamura, Kaori ^a   Deguchi, Eiichi ^a   Tokiwa, Kazuaki ^a   Iwai, Naomi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

cystic hygroma; intralesinal therapy; lymphangioma; OK 432 therapy; sclerosing therapy

Indexed keywords

PICIBANIL; TUMOR NECROSIS FACTOR;

ADULT; CLINICAL ARTICLE; CONFERENCE PAPER; CYST FLUID; CYSTIC LYMPHANGIOMA; CYTOLOGY; DRUG MECHANISM; FEMALE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; NATURAL KILLER CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCLEROTHERAPY;

EID: 0029960071     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3468(96)90478-9     Document Type: Conference Paper

References (19)

1. Ogita S, Tsuto T, Takahashi T: A case report of sclerosing therapy with OK-432 for cystic hygroma in a child. Geka (Surgery) 49:421-423, 1987
2. Ishida N, Hoshino T: A Streptococcal Preparation as a Potent Biological Response Modifier OK-432 (ed 2). Amsterdam, The Netherlands, Excerpta Medica, 1985, pp 60-62
3. Ogita S, Tsuto T, Tokiwa K, et al: Intracystic injection of OK-432; A new sclerosing therapy for cystic hygroma in children. Br J Surg 74:690-691, 1987
4. Ogita S, Tsuto T, Deguchi E, et al: OK-432 therapy for unresectable lymphangioma in children. J Pediatr Surg 26:263-270, 1991
5. Ogita S, Tsuto T, Nakamura K, et al: OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg 29:784-785, 1994
6. Uchida A, Mieksche M: Intrapleural administration of OK-432 in cancer patients: Activation of NK cells and reduction of suppressor cells. Int J Cancer 31:1-5, 1983
7. Yoshie O, Tada K, Ishida N: Binding and crosslinking of 125I-labeled recombinant human TNF to cell surface receptors. J Biochem 100:531-541, 1986
8. Okamoto H: Experimental anticancer studies. Part XXXI. On the streptococcal preparation having potent anticancer activity. Jpn J Exp Med 36:175-186, 1966
9. Uchida A, Hoshina T: Clinical studies on cell-mediated immunity in patients with malignant disease. Cancer 45:476-483, 1980
10. Watanabe Y, Iwa T: Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 53:248-253, 1984
11. Noda T, Teshima K, Suzuki H, et al: Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cancer 60:2394-2402, 1987
12. Torisu M, Katano M, Kimura Y, et al: New approach to malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93:357-364, 1983
13. Katano M, Torisu M: Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer 50:62-68, 1982
14. Saito M, Ichimura O, Kataoka M, et al: Pronounced antitumor effect of LAK-like cells induced in peritoneal cavity of mice after peritoneal injection of OK-432, a killed streptococcal preparation. Cancer Immunol Immunother 22:161-168, 1986
15. Moriya Y, Sato H, Ito K, et al: Induction of antitumor L3T4-positive T cells by OK-432 at tumor site in mice. Cancer Immunol Immunother 35:245-250, 1993
16. Mori H, Itoh N, Tamaya T: Mechanisms of induction of endogenous tumor necrosis factor in ascites of ovarian cancer patients by OK-432, a streptococcal preparation. Immunopharmacol Immunotoxicol 11:33-53, 1989
17. Tsuchihashi Y, Ogita S: Histopathological study of the effect of OK-432 on lymphangioma of an infant. J Kyoto Pref Univ Med 102:1055-1060, 1993
18. Ishida N, Saito M: How have we elucidated the mechanism of action of OK-432? - Effector cells and cytokine induction. Biotherapy 4:155-165, 1990
19. Anghilei LJ, Robert H: Effects of tumor necrosis factor on tumor cell plasma membrane permeability. Tumori 73:269-271, 1987